Trial Profile
A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2023
Price :
$35
*
At a glance
- Drugs Selinexor (Primary)
- Indications Thymic epithelial tumour; Thymoma
- Focus Therapeutic Use
- Acronyms SELECT
- 18 Apr 2022 Status changed from active, no longer recruiting to discontinued.
- 11 Aug 2021 Status changed from recruiting to active, no longer recruiting.
- 17 Feb 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.